Volume 17 Issue 1, April 2023

By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.

The precision medicine services company Oncolines B.V. is accelerating cancer drug development by identifying drug response biomarkers in over 200 genetically characterized cancer cell lines.

Heligenics is using its first-in-class platform for whole-gene drug-resistance profiling to progress precision prescriptions.

Recent oncology dealmaking trends provide insights on strategies for dealmaking in the current market.

Eterna Therapeutics is using state-of-the-art messenger RNA (mRNA) technology to develop cell and gene therapies for cancer and a wide range of other indications.

Ellipses Pharma’s KOL-enabled cloud-based platform is crowdsourcing expert insight from oncologists worldwide to create tailored opportunities for developing drug candidates.

Strike Pharma has developed new affinity-based linkers for optimized delivery of tumor-specific immunogenic peptides to immune cells, creating more efficacious personalized immunotherapies with fewer side effects.

A next-generation diagnostic test developed by Haystack Oncology detects the presence of minimal residual disease in early-stage cancer patients after curative-intent surgery. By identifying residual disease—which Haystack achieves through accurately measuring circulating tumor DNA in blood—clinicians can make more-informed decisions to help their patients achieve better outcomes.

New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ) T cell biology to merge innate and adaptive immune capabilities against cancer.

LR 09, a metabolic immune-checkpoint inhibitor that can initiate graft-versus-leukemia effect in relapsed allogeneic stem-cell transplant (SCT) patients, could become the new standard of care for leukemia.

Affivant Sciences is developing tetravalent, bispecific antibodies that can recruit multiple innate immune-cell types to attack a range of challenging cancers.

The Korea Drug Development Fund (KDDF), through its investment and support of the biopharma sector, translates cutting-edge science into patient benefits and market opportunities.

With a lead candidate harnessing antibody-driven cytotoxic mechanisms to drive tumor cell death, Byondis is developing a pipeline of candidates targeting oncology by combining its unrivaled expertise in linker-drug technology, antibody–drug conjugation, targeted cytotoxic therapy and the development of monoclonal antibodies.